Uncommon Profit Investor
Contributor since: 2014
Latest Articles
Ionis Investors And Management Should Focus On Success In Neurology
Did Bernie Sanders Attack Medivation Without Reading Its Annual Reports?
Will Ionis And Biogen Get An Early Approval For Nusinersen?
Gilead Will Go Lower And Lower Unless It Changes Course
Generic Drug Stock Warning Comes True As Endo Crashes
Gilead: Mistakes Made By Bulls And Bears
Strange Gilead Should Start By Buying Medivation
Ionis: Catalyst Pending, Ignore The Drop
More Breakthroughs At Ionis Pharmaceuticals
This Could Be Valeant's Route To Bankruptcy
Roadmap To Profit From Valeant's Collapse And The Political State Of Affairs
FDA Prepares To Torpedo Valeant And Other Generic Drug Companies
Ionis Has A Bright Future
Ionis Could Spike Due To Breakthrough
Overlooked Facts In FireEye
Demystifying The Valeant-Walgreens Deal
Express Scripts Is A Better Investment Than CVS
Express Scripts: After Turing, Is Valeant Next?
PBMs Can Shut Down Valeant
Express Scripts Is A Cash Machine
How Valeant's Largest Shareholder Missed Warren Buffett's And Charlie Munger's Warnings
I Was Right About Buffett's Opinion Of Valeant
Horizon Hit By Express Scripts, Valeant Back To Square One
Valeant - Why Bill Ackman Is Scared
Valeant's Sum-Of-Parts Liquidation Value
The Next Hole In Valeant's Boat
The Biggest Threat To Valeant
The FBI Should Investigate Valeant-Philidor For Insurance Fraud
Generic Drug Stocks Continue To Slide
Mallinckrodt: A Valeant Clone That Has Imploded
Biogen Is Not Valeant
Illumina Blindsided By Abrupt Foreign Market Slowdown, Waters May Be Next